Latest Conference Articles

Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, elicited encouraging response rates in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 1/2 study.

Mosunetuzumab, an off-the-shelf outpatient therapy with a fixed duration of treatment, demonstrated promising responses in patients with relapsed/refractory follicular lymphoma.

Aaron T. Gerds, MD, MS, unpacks data seen with momelotinib for patients with anemic myelofibrosis.

Non-Hispanic Black patients with hormone receptor (HR)–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, even with similar 21-gene recurrence scores.

Neoadjuvant pertuzumab/trastuzumab increased the rate of pathological complete response in patients with HER2-positive breast cancer.

Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.

Patients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.

In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.

Camizestrant doubled progression-free survival compared with fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer.

Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent radiotherapy did not experience a significant drop in ejection fraction or global longitudinal strain.

Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.

Blinatumomab plus consolidation chemotherapy demonstrated a survival advantage for patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.

Ribociclib showed a significant reduction in risk of disease progression in patients with pre- and perimenopausal HR+, HR- advanced breast cancer.

Longer duration of CDK4/6 inhibitor prior to treatment with elacestrant correlated with progression-free survival (PFS) improvements in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer vs standard-of-care options.

Patients with acute lymphoblastic leukemia who received vincristine-based regimens with TKIs did not experience more chemotherapy-induced peripheral neuropathy vs those who did not.

Treatment with chemotherapy, including taxane-based chemotherapies, in the adjuvant setting did not yield significant differences in breast-cancer related lymphedema risk.

In real-world practice, use of ovarian suppression therapy was not common among premenopausal patients with hormone receptor–positive, HER2-positive breast cancer, with tamoxifen being the preferred endocrine therapy.

Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.

Adding daratumumab to bortezomib, lenalidomide, and dexamethasone showed meaningful improvements in patient-reported outcomes in the phase 2 GRIFFIN trial.

In the second-line setting, patients with advanced HER2-positive breast cancer derived a superior clinical benefit with trastuzumab deruxtecan compared with treatment with physician’s choice of treatment.

Findings from the POSITIVE trial suggest that pausing endocrine therapy to pursue pregnancy did not negatively affect outcomes for patients with breast cancer.

A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.

Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.

New findings suggest that neoadjuvant therapy with antibody-drug conjugates may be effective for patients with early-stage breast cancer.

Psychiatric distress and existential distress are associated with poor outcomes in patients with advanced cancers and treatment options such as psychotherapy have demonstrated limited effectiveness.

During the 40th Annual Chemotherapy Foundation Symposium, Jeffrey S. Weber, MD, PhD, discussesed best sequencing practices in metastatic melanoma.

Manmeet Ahulwalia, MD, MBA, underscores how novel treatment approaches in oncology are proving effective in managing brain metastases.

During the 40th Annual Chemotherapy Foundation Symposium, Sandra Kurtin, PhD, ANP-BC, FAPO, discussed improving health literacy in oncology care.

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.